Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

10.4. Preparation of anti-GFP nanobody resin

DK David M. Kern
SB Stephen G. Brohawn
request Request a Protocol
ask Ask a question
Favorite

Note: Anti-GFP nanobody resin can be obtained multiple ways. First, you can buy it pre-made from a company. Second, you can buy CNBr-activated Sepharose and couple it (following manufacturer's instructions) to prepared anti-GFP nanobody. Finally, you can buy Sepharose resin, activate it with CNBr in your laboratory, and couple it to prepared anti-GFP nanobody. This is the cheapest option, but you will need to have appropriate practices in place to handle CNBr, which is very toxic.

Note: We use ~ 1–1.5 mg anti-GFP nanobody per 1 mL of hydrated resin for coupling.

Copyright and License information:  ©2021 Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A